Gyre Therapeutics, Inc. GYRE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $37.07M+214% | $11.81M-64.7% | $33.51M+33.1% | $25.18M-43.2% | ||
| $15.36M+3.3% | $14.86M— | —— | —— | ||
| $101.73M+39.1% | $73.16M+258% | $20.41M+31.1% | $15.56M+163% | ||
| $35.76M+53.6% | $23.29M+757% | $2.72M-59.9% | $6.78M— | ||
| $102.37M+58.0% | $64.79M+13.2% | $57.22M+15.2% | $49.65M-3.5% | ||
| $23.6M-1.2% | $23.88M+2.5% | $23.29M+31.5% | $17.71M+1,726% | ||
| $4.73M+1,632% | $273K0.0% | $273K-8.1% | $297K— | ||
| $166.13M+32.5% | $125.41M+7.6% | $116.54M+37.5% | $84.75M+52.3% | ||
| $124K+14.8% | $108K-69.6% | $355K+191% | $122K-98.1% | ||
| $14K-77.0% | $61K+56.4% | $39K-66.9% | $118K-48.7% | ||
| $18.29M-6.3% | $19.52M-2.6% | $20.05M+63.8% | $12.24M-13.6% | ||
| $23.85M-11.7% | $27M-29.1% | $38.07M+204% | $12.54M-14.0% | ||
| $91K+5.8% | $86K+11.7% | $77K+20.3% | $64K+106% | ||
| -$68.43M+6.8% | -$73.45M+14.1% | -$85.54M-1,257% | $7.4M+102% | ||
| $106.03M+67.5% | $63.32M+500% | -$15.83M-137% | $42.52M+3.5% | ||
| $166.13M+32.5% | $125.41M+7.6% | $116.54M+37.5% | $84.75M+52.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s total assets?
- Gyre Therapeutics, Inc. (GYRE) holds $162.0M in total assets, up 24.8% year over year.
- How much debt does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. carries $823.0K in total debt against $101.3M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. holds $37.5M in cash and equivalents.
- Can Gyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.64 — current assets exceed current liabilities.
- Where does Gyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
